PT-141 (Bremelanotide) Research Guide

PT-141 has one of peptide science's better origin stories: researchers studying Melanotan II noticed effects that pigmentation couldn't explain, traced them to a metabolite, and developed that metabolite into a compound that eventually completed clinical development as bremelanotide (Vyleesi).

Receptor profile

PT-141 is a cyclic heptapeptide melanocortin agonist with meaningful activity across MC1R and MC4R — the latter being the centrally-expressed receptor associated in the literature with its distinctive effects. Its relative MC4R weighting versus Melanotan II makes the pair a natural selectivity comparison.

Research applications

MC4R signalling studies, receptor-subtype selectivity assays, and CNS-receptor work dominate. The completed clinical program means unusually complete published pharmacology for a research peptide — receptor kinetics, metabolism, the lot.

Handling and sourcing

Cyclic structure gives decent stability; standard lyophilised protocol applies. Store dark. 10mg vials, ≥99% HPLC-verified, batch documentation on request, express from Australia.

If you run a peptide business, or are building one, we wholesale Australian-sourced stock to trade buyers across Australia.

All compounds discussed are for in-vitro laboratory research only and are not for human or veterinary use.